ADCETRIS Market Summary

Key Factors Driving ADCETRIS Growth

1. Increasing use in first-line Hodgkin lymphoma is the core growth driver:

ADCETRIS is increasingly being incorporated into frontline treatment of advanced classical Hodgkin lymphoma (cHL), particularly through the A+AVD regimen (brentuximab vedotin + doxorubicin, vinblastine and dacarbazine). Takeda reported that ADCETRIS growth has been primarily driven by increased first-line Hodgkin lymphoma use. In the first half of FY2025, ADCETRIS growth was 11.5% at constant exchange rates (CER). A recent meta-analysis of four randomized trials involving 3,591 patients also found that BV-containing frontline regimens significantly improved progression-free survival versus non-BV regimens (HR 0.58).

2. New European frontline approval with BrECADD expands the addressable market:

In June 2025, the European Commission approved ADCETRIS with ECADD (BrECADD) for adults with newly diagnosed Stage IIB with risk factors, Stage III or Stage IV Hodgkin lymphoma. The approval was based on the Phase III HD21 trial, in which BrECADD demonstrated non-inferior PFS and superior treatment-related morbidity compared with eBEACOPP. This provides another frontline ADCETRIS-based regimen in Europe and could support additional utilization in advanced-stage disease.

3. Expansion into relapsed/refractory large B-cell lymphoma provides a significant new opportunity:

In February 2025, the FDA approved ADCETRIS in combination with lenalidomide + rituximab for adults with relapsed/refractory LBCL after ≥2 systemic therapies who are ineligible for autologous HSCT or CAR-T therapy. In ECHELON-3, median overall survival was 13.8 months with ADCETRIS + R² versus 8.5 months with R² alone (HR 0.63). The overall response rate was also higher at 64% versus 42%, creating a new commercial opportunity beyond Hodgkin lymphoma and systemic anaplastic large-cell lymphoma.

4. Broad CD30-positive lymphoma footprint supports recurring demand:

ADCETRIS is a CD30-directed antibody-drug conjugate that delivers the microtubule-disrupting agent MMAE into CD30-positive malignant cells. Its established indications span classical Hodgkin lymphoma, systemic anaplastic large-cell lymphoma, peripheral T-cell lymphoma and CD30-expressing cutaneous T-cell lymphoma, with additional indications in different regions. Takeda reports that ADCETRIS has received regulatory authorization in 80 countries for relapsed/refractory Hodgkin lymphoma and sALCL, providing a broad international commercial base.

5. International penetration, particularly Europe and Growth & Emerging Markets, is supporting revenue growth:

Takeda's FY2026 results show that ADCETRIS generated JPY 140.2 billion (~US$0.95 billion at a simple ¥147/US$ conversion) for the fiscal year ended March 31, 2026, an 8.7% increase at actual exchange rates and 5.3% at CER. Takeda specifically attributed the increase to strong demand in Europe and Growth & Emerging Markets. In Q1 FY2026 (April–June 2026), sales reached JPY 48.5 billion, up 14.4% at CER, with growth led particularly by Latin America.

ADCETRIS Recent Developments

In February 2025, the US FDA approved a new combination regimen utilizing ADCETRIS alongside lenalidomide and a rituximab product. This landmark eighth US indication is for adults with relapsed or refractory large B-cell lymphoma (including DLBCL) who have received at least two prior lines of systemic therapy and are ineligible for stem cell transplants or CAR T-cell therapy. The approval was backed by positive overall survival data from the Phase III ECHELON-3 clinical trial.

“ADCETRIS Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of ADCETRIS for approved indication like Diffuse large B cell lymphoma, Anaplastic large cell lymphoma, and Hodgkin’s disease; as well as potential indication like Adult T-cell leukaemia-lymphoma, Diffuse scleroderma, Germ cell cancer, Malignant-mesothelioma, Mastocytosis, Non-Hodgkin’s lymphoma in the 7MM. A detailed picture of ADCETRIS’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the ADCETRIS for approved and potential indications. The ADCETRIS market report provides insights about ADCETRIS’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ADCETRIS performance, future market assessments inclusive of the ADCETRIS market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ADCETRIS sales forecasts, along with factors driving its market.

ADCETRIS Drug Summary

ADCETRIS is an antibody–drug conjugate (ADC) developed by Seagen, now part of Pfizer, that targets CD30, a cell-surface marker expressed on malignant cells in Hodgkin lymphoma and several other CD30-positive lymphomas. The drug consists of a recombinant chimeric IgG1 monoclonal antibody directed against CD30, linked through a protease-cleavable linker to the potent antimitotic agent monomethyl auristatin E (MMAE). Following intravenous administration, brentuximab vedotin binds to CD30-expressing tumor cells and is internalized, after which proteolytic cleavage releases MMAE inside the cell. MMAE binds to tubulin and disrupts the microtubule network, leading to cell-cycle arrest and apoptotic death of the malignant cell. ADCETRIS is approved for multiple CD30-positive hematologic malignancies, including classical Hodgkin lymphoma, systemic anaplastic large cell lymphoma (sALCL), and certain peripheral T-cell lymphomas, with indications varying by treatment setting and combination regimen. Its clinical use is associated with important adverse effects such as peripheral neuropathy, neutropenia, serious infections, infusion-related reactions, and progressive multifocal leukoencephalopathy (PML), requiring appropriate monitoring during treatment. The report provides ADCETRIS’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ADCETRIS Market Report

The report provides insights into:

• A comprehensive product overview including the ADCETRIS MoA, description, dosage and administration, research and development activities in approved indications like Diffuse large B cell lymphoma, Anaplastic large cell lymphoma, and Hodgkin’s disease; as well as potential indication like Adult T-cell leukaemia-lymphoma, Diffuse scleroderma, Germ cell cancer, Malignant-mesothelioma, Mastocytosis, Non-Hodgkin’s lymphoma.
• Elaborated details on ADCETRIS regulatory milestones and other development activities have been provided in ADCETRIS market report.
• The report also highlights ADCETRIS‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The ADCETRIS market report also covers the patents information, generic entry and impact on cost cut.
• The ADCETRIS market report contains current and forecasted ADCETRIS sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ADCETRIS market report also features the SWOT analysis with analyst views for ADCETRIS in approved and potential indications.

Methodology

The ADCETRIS market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ADCETRIS Analytical Perspective by DelveInsight

• In-depth ADCETRIS Market Assessment

This ADCETRIS sales market forecast report provides a detailed market assessment of ADCETRIS for approved indication like Diffuse large B cell lymphoma, Anaplastic large cell lymphoma, and Hodgkin’s disease; as well as potential indication like Adult T-cell leukaemia-lymphoma, Diffuse scleroderma, Germ cell cancer, Malignant-mesothelioma, Mastocytosis, Non-Hodgkin’s lymphoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ADCETRIS sales data uptil 2034.

• ADCETRIS Clinical Assessment

The ADCETRIS market report provides the clinical trials information of ADCETRIS for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ADCETRIS Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ADCETRIS Market Potential & Revenue Forecast

• Projected market size for the ADCETRIS and its key indications
• Estimated ADCETRIS sales potential (ADCETRIS peak sales forecasts)
• ADCETRIS Pricing strategies and reimbursement landscape

ADCETRIS Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ADCETRIS Market positioning compared to existing treatments
• ADCETRIS Strengths & weaknesses relative to competitors

ADCETRIS Regulatory & Commercial Milestones

• ADCETRIS Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ADCETRIS Clinical Differentiation

• ADCETRIS Efficacy & safety advantages over existing drugs
• ADCETRIS Unique selling points

ADCETRIS Market Report Highlights

• In the coming years, the ADCETRIS market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ADCETRIS companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ADCETRIS’s dominance.
• Other emerging products for Diffuse large B cell lymphoma, Anaplastic large cell lymphoma, and Hodgkin’s disease; as well as potential indication like Adult T-cell leukaemia-lymphoma, Diffuse scleroderma, Germ cell cancer, Malignant-mesothelioma, Mastocytosis, Non-Hodgkin’s lymphoma are expected to give tough market competition to ADCETRIS and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ADCETRIS in approved and potential indications.
• Analyse ADCETRIS cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ADCETRIS sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ADCETRIS in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of ADCETRIS? How strong is ADCETRIS’s clinical and commercial performance?
• What is ADCETRIS’s clinical trial status in each individual indications such as Diffuse large B cell lymphoma, Anaplastic large cell lymphoma, and Hodgkin’s disease; as well as potential indication like Adult T-cell leukaemia-lymphoma, Diffuse scleroderma, Germ cell cancer, Malignant-mesothelioma, Mastocytosis, Non-Hodgkin’s lymphoma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ADCETRIS Manufacturers?
• What are the key designations that have been granted to ADCETRIS for approved and potential indications? How are they going to impact ADCETRIS’s penetration in various geographies?
• What is the current and forecasted ADCETRIS market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ADCETRIS in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ADCETRIS for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is ADCETRIS? What is the duration of therapy and what are the geographical variations in cost per patient?